Q&A With Maha Radhakrishnan From Biogen: Zinbryta Looks To Bring New Tool to Multiple Sclerosis Treatent Battle

While there are already several medications and treatments on the market for relapsing multiple sclerosis there continues to be a concerted effort to develop more in an effort to help as many patients as possible.

While there are already several medications and treatments on the market for relapsing multiple sclerosis there continues to be a concerted effort to develop more in an effort to help as many patients as possible.

Maha Radhakrishnan, MD, Vice Presdient of the European and Canadian medical groups at Biogen discussed the development of the new treatment option and what it could mean to patient care if approved by the regulatory bodies.